Physician profile
Gina Wang
NPI 1629091426
$4,094.08
in general payments reported to CMS, 2019-2025
14 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $494 · 2021: $793 · 2022: $674 · 2023: $340 · 2024: $656 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,961.57 | 2019-2024 | Xifaxan |
| Abbvie INC. | $1,524.46 | 2019-2024 | Linzess, Creon, Viberzi |
| Madrigal Pharmaceuticals | $187.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $125.42 | 2024 | Voquezna |
| Gilead Sciences, INC. | $56.84 | 2019-2021 | |
| Exact Sciences Corporation | $53.14 | 2025 | The Cologuard Plus Collection Kit |
| Ironwood Pharmaceuticals, INC | $45.49 | 2024 | |
| Astellas Pharma US INC | $29.87 | 2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $24.06 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $23.36 | 2025 | |
| Ardelyx, INC. | $20.26 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $17.21 | 2019 | |
| Intercept Pharmaceuticals, INC. | $12.25 | 2020 | |
| Redhill Biopharma INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.